What could cause a low plasma renin level in a patient who is not taking fludrocortisone?

Low Plasma Renin in the Absence of Fludrocortisone

Low plasma renin without fludrocortisone therapy indicates either primary aldosteronism, other mineralocorticoid excess states, volume expansion from essential hypertension, chronic kidney disease, or rare genetic syndromes—and requires measurement of aldosterone and potassium to differentiate these conditions.

Diagnostic Algorithm Based on Aldosterone and Potassium

The key to diagnosing low-renin states is examining aldosterone levels alongside potassium, as this creates distinct diagnostic pathways 1:

High Aldosterone + Low Renin (Inappropriate Aldosterone)

• Primary aldosteronism (PA): Most common pathologic cause
  • Screen with aldosterone-to-renin ratio (ARR) 1
  • Consider PA when aldosterone >10 ng/dL by immunoassay with suppressed renin 1
  • Accounts for significant proportion of resistant hypertension 2
  • Often associated with hypokalemia (though only 9-37% present with hypokalemia) 1

Normal/Low Aldosterone + Low Renin

• Volume-expanded essential hypertension: Approximately 25% of hypertensive patients have low renin as a physiological response to sodium-volume overload 3
• Chronic kidney disease: Renin decreases proportionately to nephron loss, except when renal artery stenosis is present 1
• Genetic syndromes 3, 4:
  • Liddle syndrome (gain-of-function ENaC mutations)
  • Apparent mineralocorticoid excess (11β-HSD2 deficiency)
  • Glucocorticoid-remediable aldosteronism
  • 11β-hydroxylase deficiency 5

Critical Interpretation Considerations

Medication interference must be excluded first 1:

• β-blockers and centrally acting α₂-agonists (clonidine, methyldopa) suppress renin and cause false-positive low readings
• Withdraw these medications for 2 weeks if safe before interpreting results
• MRAs, diuretics, ACE inhibitors, and ARBs should be withdrawn for 2-4 weeks as they raise renin

Laboratory and clinical context matters 1:

• Ensure proper blood collection technique (slow draw, avoid fist clenching, separate plasma within 30 minutes)
• Correct hypokalemia before testing, as it suppresses aldosterone
• Local laboratory reference ranges vary by assay—use institution-specific cutoffs
• Recent evidence suggests plasma renin activity (PRA) by LC-MS/MS may perform better than plasma renin concentration (PRC) for clinical decision-making 6

Clinical Significance and Treatment Implications

Low-renin hypertension is therapeutically important 2:

• In therapy-resistant hypertension, 67% had low renin status
• These patients responded dramatically to aldosterone inhibition (blood pressure reduction of 31/15 mmHg)
• 18% showed escape phenomenon requiring increased aldosterone blockade

Monitoring renin in treated patients 7:

• Renin <20 mIU/L suggests mineralocorticoid oversubstitution
• Renin 20-60 mIU/L indicates appropriate replacement
• Renin >60 mIU/L suggests undersubstitution
• Renin correlates better with dose changes than electrolytes or blood pressure alone

Common Pitfalls to Avoid

1. Don't rely solely on potassium: Most PA patients are normokalemic 1
2. Don't ignore suppressed renin with borderline aldosterone: If renin is suppressed with aldosterone 5-10 ng/dL, repeat testing on a different day 1
3. Don't forget CKD as a cause: Renin naturally decreases with nephron loss, leading to false-positive PA screening 1
4. Don't overlook blood pressure: Suppressed renin is associated with highest probability of hypertension 8